JP4733642B2 - 第Xa因子阻害剤としてのアザインドール−誘導体 - Google Patents

第Xa因子阻害剤としてのアザインドール−誘導体 Download PDF

Info

Publication number
JP4733642B2
JP4733642B2 JP2006529743A JP2006529743A JP4733642B2 JP 4733642 B2 JP4733642 B2 JP 4733642B2 JP 2006529743 A JP2006529743 A JP 2006529743A JP 2006529743 A JP2006529743 A JP 2006529743A JP 4733642 B2 JP4733642 B2 JP 4733642B2
Authority
JP
Japan
Prior art keywords
alkyl
unsubstituted
heterocyclyl
independently
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006529743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528214A5 (cg-RX-API-DMAC7.html
JP2006528214A (ja
Inventor
マルク・ナザレ
フォルクマール・ヴェーナー
デイヴィッド・ウィリアム・ウィル
クルト・リッター
マティーアス・ウーアマン
ハンス・マター
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2006528214A publication Critical patent/JP2006528214A/ja
Publication of JP2006528214A5 publication Critical patent/JP2006528214A5/ja
Application granted granted Critical
Publication of JP4733642B2 publication Critical patent/JP4733642B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2006529743A 2003-05-19 2004-05-05 第Xa因子阻害剤としてのアザインドール−誘導体 Expired - Fee Related JP4733642B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03011304.7 2003-05-19
EP03011304A EP1479680A1 (en) 2003-05-19 2003-05-19 Azaindole derivatives as Factor Xa inhibitors
PCT/EP2004/004754 WO2004101563A1 (en) 2003-05-19 2004-05-05 AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (3)

Publication Number Publication Date
JP2006528214A JP2006528214A (ja) 2006-12-14
JP2006528214A5 JP2006528214A5 (cg-RX-API-DMAC7.html) 2007-05-17
JP4733642B2 true JP4733642B2 (ja) 2011-07-27

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529743A Expired - Fee Related JP4733642B2 (ja) 2003-05-19 2004-05-05 第Xa因子阻害剤としてのアザインドール−誘導体

Country Status (24)

Country Link
EP (2) EP1479680A1 (cg-RX-API-DMAC7.html)
JP (1) JP4733642B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060012636A (cg-RX-API-DMAC7.html)
CN (1) CN100347172C (cg-RX-API-DMAC7.html)
AR (1) AR045682A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004238500B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0410429A (cg-RX-API-DMAC7.html)
CA (1) CA2526084A1 (cg-RX-API-DMAC7.html)
CL (1) CL2004001079A1 (cg-RX-API-DMAC7.html)
CR (1) CR8088A (cg-RX-API-DMAC7.html)
EC (1) ECSP056179A (cg-RX-API-DMAC7.html)
MA (1) MA27799A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05012156A (cg-RX-API-DMAC7.html)
NO (1) NO20055911L (cg-RX-API-DMAC7.html)
NZ (1) NZ543669A (cg-RX-API-DMAC7.html)
OA (1) OA13169A (cg-RX-API-DMAC7.html)
PE (1) PE20050554A1 (cg-RX-API-DMAC7.html)
RS (1) RS20050857A (cg-RX-API-DMAC7.html)
RU (1) RU2330853C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN05296A1 (cg-RX-API-DMAC7.html)
TW (1) TW200510411A (cg-RX-API-DMAC7.html)
UA (1) UA86767C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004101563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200508150B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622466B2 (en) * 2005-11-18 2009-11-24 Hoffman-La Roche Inc. Azaindole-2-carboxamide derivatives
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9345247B2 (en) 2012-08-17 2016-05-24 Bayer Cropscience Ag Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
ZA953361B (en) 1994-04-26 1996-01-12 Selectide Corp Factor Xa inhibitors
ZA964008B (en) * 1995-06-02 1997-07-11 Akzo Nobel Nv Imidazo[1,5a]pyridine derived serine protease inhibitors
NZ503809A (en) * 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
BR9814340B1 (pt) * 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
CZ2002961A3 (cs) * 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002070523A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
AU2002303264A1 (en) * 2001-04-09 2002-10-21 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
EA012926B1 (ru) * 2001-12-20 2010-02-26 Оси Фармасьютикалз, Инк. Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
WO2004101563A1 (en) 2004-11-25
CL2004001079A1 (es) 2005-04-08
MXPA05012156A (es) 2006-08-18
CN1791601A (zh) 2006-06-21
NO20055911L (no) 2006-02-10
EP1479680A1 (en) 2004-11-24
TNSN05296A1 (en) 2007-07-10
RU2005139557A (ru) 2007-06-27
CR8088A (es) 2006-09-22
ECSP056179A (es) 2006-08-30
EP1636226A1 (en) 2006-03-22
AU2004238500B2 (en) 2010-07-22
UA86767C2 (ru) 2009-05-25
ZA200508150B (en) 2007-02-28
RS20050857A (sr) 2007-11-15
NZ543669A (en) 2008-12-24
BRPI0410429A (pt) 2006-06-06
AR045682A1 (es) 2005-11-09
AU2004238500A1 (en) 2004-11-25
OA13169A (en) 2006-12-13
RU2330853C2 (ru) 2008-08-10
EP1636226B1 (en) 2014-10-15
CA2526084A1 (en) 2004-11-25
TW200510411A (en) 2005-03-16
JP2006528214A (ja) 2006-12-14
HK1089175A1 (zh) 2006-11-24
KR20060012636A (ko) 2006-02-08
CN100347172C (zh) 2007-11-07
PE20050554A1 (es) 2005-08-04
MA27799A1 (fr) 2006-03-01

Similar Documents

Publication Publication Date Title
JP4676960B2 (ja) 第Xa因子阻害剤としてのインドール誘導体
JP4585448B2 (ja) 第Xa因子阻害剤としてのピラゾール−誘導体
JP4709763B2 (ja) 第Xa因子阻害剤としてのインダゾール誘導体
US20080280946A1 (en) Azaindole-Derivatives As Factor Xa Inhibitors
US7465806B2 (en) Pyrrole-derivatives as factor Xa inhibitors
AU2002351918B2 (en) Indole-2-carboxamides as factor Xa inhibitors
US7223780B2 (en) Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
JP4608495B2 (ja) 第Xa因子阻害剤としてのトリアゾール誘導体
US7741341B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
JP4658940B2 (ja) 第Xa因子阻害剤としてのベンゾイミダゾール誘導体
AU2004238500B2 (en) Azaindole-derivatives as factor Xa inhibitors

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20060117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070320

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101115

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110422

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140428

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees